AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00742703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mineralized water
Study NCT00742703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low mineralized water
Study NCT05709730 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HPV genotyping
Description: HPV genotyping of samples classified that were positive for other HPV
Study NCT05130112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula and nasal cannula
Description: HFNC was administered using the MyAIRVO 2 device (Fisher \& Paykel Healthcare, Auckland, New Zealand), which provides humidification and high-flow medical gas through an Optiflow NC interface (Fisher \& Paykel Healthcare, Auckland, New Zealand) is administered for 10 min..~NC is administered for 10 min.
Study NCT06535360 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet transfusion
Description: platelet administration through intravenous access
Study NCT06535360 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet transfusion
Description: platelet administration through intravenous access
Study NCT02362698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electro-acupuncture
Description: 13points were selected including he-gu(LI4), nei-guan(PC6), tai-chong(LR3) and san-yin-jiao(SP6) from both sides, bai-hui(GV20) and si-shen-cong(EX-HN1) from head.~HANS-200A acupoints stimulator, which had two output channels, was connected to some selected points. Dilatational wave was adopted in this research, the frequency of rarefaction wave was 2 hertz and condensation wave was 100 hertz, with a waviness width of 0.3ms. Switched the stimulator on after connected the poles to the needles, adjusted the intensity of output gradually from 0 milliampere to the extent of subject's maximum tolerance. Then needles would be remained on the body for half an hour.
Study NCT02362698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psychological intervention
Description: Cognitive behavioral therapy was adopted by national accredited professional psychologist, in the form of team work and individual counseling, aim to help IA participants to understand their deviant behaviors, correct unhealthy cognitive states and eventually retrieve normal life style.
Study NCT03862404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-epinephrine
Description: See previous description
Study NCT03862404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: See previous descreption
Study NCT01300130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low docosahexaenoic acid formula
Study NCT01300130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: medium docosahexaenoic acid formula
Study NCT01300130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high docosahexaenoic acid formula
Study NCT01300130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: breast milk
Description: a non randomized group of breast milk fed infants was included
Study NCT00121238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV
Study NCT02521090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFRBi-Armed Autologous T Cells
Description: Given IT and IV
Study NCT02521090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00349089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22
Study NCT00349089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22~Comparator:~Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29 Cisplatin 50 mg/m2 d1, 8; q d29
Study NCT00349089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22~Comparator:~Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29 Cisplatin 50 mg/m2 d1, 8; q d29
Study NCT00349089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29
Study NCT05369650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride, Injectable
Description: The lidocaine group 1, 1.5 and 2 groups were injected with 1% lidocaine 1.5mg/kg (ideal body weight, 10min infusion) after anesthesia induction, respectively, and then continued to infuse 1% lidocaine. 1mg/kg.h, 1.5mg/kg.h, 2mg/kg.h (ideal body weight) until the end of the operation, and a patient-controlled intravenous analgesia (PCIA) pump containing lidocaine (PCIA) 0.3-1.5mg/kg after surgery. h to 72h after surgery.
Study NCT02898974 — intervention group
Intervention type: BEHAVIORAL
Intervention: Medical Marijuana
Description: To investigate the effects of medical marijuana usage on physical function we will employ an observational case-control design
Study NCT00712842 — intervention group
Intervention type: OTHER
Intervention: Ocular blood flow measurements
Description: non-invasive haemodynamic measurements of retinal vessel diameters and laser Doppler velocimetry
Study NCT04229706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Xiang Ju Ru Pi Ning capsule
Description: xingjurupining capsule,8 capsule,tid,3 months.
Study NCT04229706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Xiang Ju Ru Pi Ning capsule
Description: xiangjurupining capsule,4 capsules , and xiangjurupining capsule placebo,4 capsules,tid,3 months.
Study NCT04229706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xiang Ju Ru Pi Ning capsule placebo
Description: xiangjurupining capsule,8 capsule,tid,3 months.
Study NCT01426191 — intervention group
Intervention type: DRUG
Intervention: xinzhijun
Description: durg:Cefotaxime sodium and sulbactam sodium for injection(2:1)~1.5-3.0g,iv,bid or tid for 5-12 days;~Serious infections:1.0-1.5g,iv,tid or qid for 5-12 days
Study NCT03043664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: Somatuline depot (lanreotide) 90 mg SQ every 3 weeks
Study NCT03043664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Keytruda (pembrolizumab) 200 mg IV every 3 weeks
Study NCT01973933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Pyrimethamine
Study NCT02868060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Study NCT01540851 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care Navigator
Description: Subjects assigned to the Care Navigator intervention group will receive 10 calls from a care navigator after discharge from the hospital for 5 months after their total knee replacement.
Study NCT01540851 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Post-Operative TKA Care
Description: Subjects assigned to the Standard Post-Operative TKA Care group will receive the current standard of care for post-operative care
Study NCT01507220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine sulfate
Description: Patients in this group will receive IV morphine sulfate (or Sponsor-approved equivalent) via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour. All morphine sulfate (Group 1) patients will receive the same opioid in their PCA pump.
Study NCT01507220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine liposome extended-release injectable suspension
Description: Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed.
Study NCT04457011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Susu Xiao'er Zhike Granules 1 bag
Description: High dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 20.25 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
Study NCT04457011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Middle dose Susu Xiao'er Zhike Granules 1 bag
Description: Middle dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 10.12 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
Study NCT04457011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Extremely-low dose Susu Xiao'er Zhike Granules 1 bag
Description: Extremely-low dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 1.01 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
Study NCT01874522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102 tablets
Description: Crossover bioavailability part: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout.~Extension part: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Study NCT01874522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102 oral solution
Description: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout
Study NCT03713437 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of differentially methylated insulin DNA
Description: A serum sample will be drawn to measure differentially methylated insulin DNA.
Study NCT03578276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate 1% ophthalmic suspension
Description: Steroidal anti-inflammatory
Study NCT03925402 — intervention group
Intervention type: DRUG
Intervention: Ertapenem
Description: Ertapenem injection
Study NCT03925402 — intervention group
Intervention type: DRUG
Intervention: Carbapenems
Description: Other carbapenems injection
Study NCT03578276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gatifloxacin Ophthalmic
Description: Antibiotic
Study NCT03578276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac 0.075% Oph Solution
Description: Non-steroidal anti-inflammatory
Study NCT03413865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visits conducted via Telemedicine
Description: Patients will be followed via telemedicine with visits lead by a Pharmacist and a Nurse
Study NCT01077115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Study NCT01077115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Surgery
Study NCT01901315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Online consultation
Description: Patients in the online consultation (intervention) group have monthly consultation with their attending psychiatrist through videoconferencing during one year. After each consultation, the medication is sent to the patient through a home delivery program. For reasons of patient safety, consultations at baseline, and after 6 and 12 months will be realized in a face-to-face form at the Institute of Psychiatry (IPq).
Study NCT01901315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Face-to-face consultation
Description: Patients in the face-to-face consultation (control) group have monthly face-to-face consultation with their attending psychiatrist during one year at the Institute of Psychiatry (IPq).
Study NCT03874806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25%-NaCl 0.9% Injectable Solution
Description: 0.25% ropivacaine administered through a nerve catheter
Study NCT03874806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2%-NaCl 0.9% Injectable Solution
Description: 0.2% ropivacaine administered through a nerve catheter
Study NCT03342508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetal Pillow
Description: see arm description
Study NCT04246190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 and D759
Description: Reference drug, CKD-501 1T and D759 1T, QD, PO
Study NCT03972813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Broadened information about cancers
Description: Caregivers receive information that HPV causes more than just cervical cancer.
Study NCT03972813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information about STDs
Description: Caregivers learn that HPV is an STD.
Study NCT03972813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information about infectious disease
Description: Caregivers learn that HPV is infectious (but information that it is an STD is omitted).
Study NCT03972813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recommendation for children 12 years old
Description: Caregivers are prompted to get their child vaccinated when the child is 12 years old.
Study NCT03972813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recommendation for children 18 years old
Description: Caregivers are prompted to get their child vaccinated when the child is 18 years old.
Study NCT03972813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard age information
Description: Caregivers are given information about when the HPV vaccination can be given in China, but no additional recommendations.
Study NCT03972813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cervical cancer
Description: Caregivers are told that HPV causes cervical cancer.
Study NCT03972813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blank information about communicability
Description: Caregivers are not given any information on how HPV is spread.
Study NCT04246190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-396
Description: Reference drug, CKD-396 1T, QD, PO
Study NCT02595333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group SF1
Description: primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
Study NCT02595333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group S1
Description: sufentanil was administered for analgesia in primary cesarean section
Study NCT02595333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group SF2
Description: sufentanil and flurbiprofen was administered for analgesia in repeated cesarean section
Study NCT02595333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group S2
Description: sufentanil was administered for analgesia in repeated cesarean section
Study NCT01365845 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon
Description: 50.4 Gy to the breast/chest wall and peripheral lymph nodes at 1.8 Gy per fraction
Study NCT01365845 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D-Proton/Conventional plan or 3D-proton only
Description: 50.4 Cobalt Gray Equivalent/Gray to the breast/chest wall and peripheral lymph nodes at 1.8 Cobalt Gray Equivalent/Gray per fraction
Study NCT01712230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist
Description: Drug: leuprolide acetate~Other Names:~Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 6 months
Study NCT03800134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg on Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and 1500mg on Day 1 of each 4-week cycle for 12 cycles during the adjuvant period
Study NCT03800134 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and Day 1 of each 4-week cycle for 12 cycles during the adjuvant period
Study NCT03800134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under the curve of 5/6 on Day 1 of each 3-week cycle for 4 cycles
Study NCT03800134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Area under the curve of 5/6 on Day 1 of each 3-week cycle for 4 cycles
Study NCT03800134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 on Day 1 of each 3-week cycle, for 4 cycles
Study NCT03800134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m2 on Day 1 of each 3-week cycle, for 4 cycles
Study NCT03800134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
Study NCT03800134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
Study NCT03800134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
Study NCT03800134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 200mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
Study NCT03800134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1250 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for 4 cycles.
Study NCT03800134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: 1250 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for 4 cycles.
Study NCT03800134 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Expected within 40 days from the last dose of Investigational Product following the completion of neoadjuvant treatment.
Study NCT03800134 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery
Description: Expected within 40 days from the last dose of Investigational Product following the completion of neoadjuvant treatment.
Study NCT04690738 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal Elastase Concentration
Description: Stool sample for fecal elastase-1 (FEC) analysis and microbiome for sequencing and analysis will be obtained pre- and post-transplant.
Study NCT04739956 — intervention group
Intervention type: OTHER
Intervention: The Hospital and Anxiety Depression Scale
Description: Patients and partners will be asked to complete the questionnaire at three time points: 1) On classification of PUL at time zero once blood is taken, 2) at the 48-hour time point after blood is taken (if 48 hour bloods are required for the patient); and 3) after definitive diagnosis and management.
Study NCT04739956 — intervention group
Intervention type: OTHER
Intervention: Point of care testing (POCT)
Description: Patients will have 1ml sample of blood taken for POCT at two time points: 1) On classification of PUL at time zero at the same time as when routine blood samples taken; and 2) at the 48-hour time point at the same time as when routine blood samples are taken (if 48 hour bloods are required).
Study NCT03270020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 70 MG/ML [Xgeva]
Description: As already described in arm description
Study NCT00747149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral
Study NCT04528147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yi Jin Jing Tiger Roaring Speech Rehabilitation
Description: A traditional Chinese medicine treatment
Study NCT04528147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Speech Rehabilitation
Description: A active speech rehabilitation method recommended by the Parkinson's Foundation of America
Study NCT04105764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: DEEP block to PTC 1-3
Study NCT04105764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium bromide
Description: MODERATE block to TOF1-2
Study NCT01712230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised cardiovascular exercise
Description: Supervised exercise, 4 days per week for 45 to 60 minutes per session for 6 months
Study NCT01712230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03196180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Given intravaginally
Study NCT03196180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Fluorouracil
Description: Given intravaginally
Study NCT01360606 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy
Description: SBRT:~Patients will receive one of the following radiation regimens:~* 50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period.~* 60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period.~* 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period.
Study NCT05079789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: Treatment with amiloride, start dose 5 mg
Study NCT05079789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Treatment with furosemide, start dose 40 mg